Research progress in co-delivery of gene and chemotherapy drugs with nanocarriers for cancer therapy.
- Author:
Wei-Guang CHEN
1
;
Shi-Bin WANG
Author Information
1. College of Chemical Engineering, Huaqiao University, Xiamen 361021, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
administration & dosage;
therapeutic use;
Drug Carriers;
Drug Delivery Systems;
Drug Resistance, Multiple;
Drug Resistance, Neoplasm;
Genetic Therapy;
methods;
Humans;
Nanostructures;
chemistry;
Nanotechnology;
methods;
Neoplasms;
genetics;
therapy;
RNA Interference;
RNA, Small Interfering;
administration & dosage;
genetics
- From:
Acta Pharmaceutica Sinica
2013;48(7):1091-1098
- CountryChina
- Language:Chinese
-
Abstract:
Current trends in nanotechnology and RNA interference technology have made the application of nanocarriers (NCS) as a novel gene and drug delivery systems very promising for the field of multidrug resistance (MDR) cancer treatment. Co-delivery of gene and chemotherapy drugs with NCS has a good synergistic effect compared with the traditional chemotherapy which can increase the amount of the drug distribution in target organ in order to reduce the toxic side effects thereby enhancing efficacy. Therefore, the advent of co-delivery systems with NCS especially in the clinical treatment of MDR has had a significant impact on the cancer treatment.
